The stock of Galectin Therapeutics Inc (GALT) has gone up by 20.25% for the week, with a 43.22% rise in the past month and a 63.79% rise in the past quarter. The volatility ratio for the week is 9.97%, and the volatility levels for the past 30 days are 7.02% for GALT. The simple moving average for the past 20 days is 29.43% for GALT’s stock, with a 57.61% simple moving average for the past 200 days.
Is It Worth Investing in Galectin Therapeutics Inc (NASDAQ: GALT) Right Now?
The 36-month beta value for GALT is at 0.87. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for GALT is 42.38M, and currently, shorts hold a 5.06% of that float. The average trading volume for GALT on April 04, 2024 was 73.00K shares.
GALT) stock’s latest price update
Galectin Therapeutics Inc (NASDAQ: GALT)’s stock price has gone rise by 13.55 in comparison to its previous close of 2.51, however, the company has experienced a 20.25% increase in its stock price over the last five trading days. Seeking Alpha reported 2024-03-20 that Interim results from the phase 2b/3 NAVIGATE study, using Belapectin for the prevention of esophageal varices in NASH Cirrhosis patients, expected Q4 of 2024. In a prior phase 2 study, it was shown that Belapectin was effective in treating patients who had not yet developed esophageal varices. Global non-alcoholic steatohepatitis market is expected to grow to $14.53 billion by 2028; 20% will develop NASH Cirrhosis and then about half will not have esophageal varices.
Analysts’ Opinion of GALT
Many brokerage firms have already submitted their reports for GALT stocks, with H.C. Wainwright repeating the rating for GALT by listing it as a “Buy.” The predicted price for GALT in the upcoming period, according to H.C. Wainwright is $12 based on the research report published on August 13, 2020 of the previous year 2020.
B. Riley FBR, on the other hand, stated in their research note that they expect to see GALT reach a price target of $11. The rating they have provided for GALT stocks is “Buy” according to the report published on February 13th, 2019.
H.C. Wainwright gave a rating of “Buy” to GALT, setting the target price at $10 in the report published on December 07th of the previous year.
GALT Trading at 46.55% from the 50-Day Moving Average
After a stumble in the market that brought GALT to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 9.62% of gains for the given period.
Volatility was left at 7.02%, however, over the last 30 days, the volatility rate increased by 9.97%, as shares surge +38.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +62.86% upper at present.
During the last 5 trading sessions, GALT rose by +20.25%, which changed the moving average for the period of 200-days by +95.21% in comparison to the 20-day moving average, which settled at $2.24. In addition, Galectin Therapeutics Inc saw 71.69% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GALT starting from ELDRED KARY, who purchase 500 shares at the price of $1.79 back on Jan 16 ’24. After this action, ELDRED KARY now owns 49,313 shares of Galectin Therapeutics Inc, valued at $893 using the latest closing price.
ELDRED KARY, the Director of Galectin Therapeutics Inc, purchase 1,598 shares at $1.79 during a trade that took place back on Jul 19 ’23, which means that ELDRED KARY is holding 48,813 shares at $2,854 based on the most recent closing price.
Stock Fundamentals for GALT
The total capital return value is set at -3.04.
Based on Galectin Therapeutics Inc (GALT), the company’s capital structure generated 6.22 points at debt to capital in total, while cash flow to debt ratio is standing at -0.46. The debt to equity ratio resting at -1.19. The interest coverage ratio of the stock is -13.64.
Currently, EBITDA for the company is -38.04 million with net debt to EBITDA at -1.22. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.77.
Conclusion
In conclusion, Galectin Therapeutics Inc (GALT) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
